Becton, Dickinson and Company (NYSE:BDX) is one of the  7 Most Undervalued Blue Chip Stocks to Invest In. On March 23, 2026, Argus lowered the price target on Becton, Dickinson and Company (NYSE:BDX) to $180 from $230 and maintained a Buy rating, citing the company’s transition toward a pure-play medtech model following the spin-off of its Biosciences and Diagnostics Solutions business. Argus also noted the stock trades at about 11.5 times forward earnings, below the 20.4 times average for its MedTech cov ...